24,162 results match your criteria American heart journal[Journal]


A randomized, double-blind, placebo-controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI study): Rationale, design, and baseline characteristics.

Am Heart J 2019 Jan 15;210:98-107. Epub 2019 Jan 15.

Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou (HEGP), Department of Cardiology, Paris, France; Université Paris-Descartes, Paris, France; INSERM U-970, Paris, France.

Background: About 30% of angina patients have persisting symptoms despite successful revascularization and antianginal therapy. Moreover, in stable patients, percutaneous coronary intervention (PCI) does not improve survival as compared with medical therapy alone. Trimetazidine, an antianginal agent devoid of hemodynamic effect, may help reducing symptoms and improving outcomes after PCI. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00028703193000
Publisher Site
http://dx.doi.org/10.1016/j.ahj.2018.12.015DOI Listing
January 2019
2 Reads

Trends in cardiorespiratory fitness: The evolution of exercise treadmill testing at a single Academic Medical Center from 1970to2012.

Am Heart J 2019 Jan 16;210:88-97. Epub 2019 Jan 16.

Duke Clinical Research Institute, Duke Medicine, Durham, NC; Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC; Duke Molecular Physiology Institute, Durham, NC.

Objective: To identify temporal trends in the use of exercise treadmill testing (ETT) and cardiorespiratory fitness (CRF) estimated by ETT in metabolic equivalents (METs).

Patients And Methods: We compiled an ETT database of all available treadmill tests-including those with concomitant stress echocardiography and nuclear perfusion imaging studies-performed at Duke University Hospital from January 1, 1970- December 31, 2012. Six different ramp protocols were used in these combined modalities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.01.001DOI Listing
January 2019
1 Read

Radial versus femoral vascular access in ST-elevation myocardial infarction: Are the results of femoral operators unfairly represented in observational research?

Am Heart J 2019 Jan 16;210:81-87. Epub 2019 Jan 16.

Institute of Cardiovascular Medicine and Science, Liverpool Heart and Chest Hospital, Liverpool.

Background: Recent randomized controlled trials comparing femoral and radial access in primary percutaneous coronary intervention (PPCI) have shown conflicting results regarding the incidence of major adverse cardiovascular events (MACE) and major bleeding.

Methods: Using data from the HEAT-PPCI trial, we compared the primary efficacy (all-cause mortality, stroke, new myocardial infarction or unplanned repeat revascularization) and safety (major bleeding BARC 3-5) outcomes at 28 days, by final access site used (radial or femoral) and by default operator type. We then assessed outcomes in femoral cases performed by both operator types. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.12.009DOI Listing
January 2019
1 Read
4.463 Impact Factor

Rationale and design of a multicenter randomized trial to compare the graft patency between no-touch vein harvesting technique and conventional approach in coronary artery bypass graft surgery.

Am Heart J 2018 Dec 6;210:75-80. Epub 2018 Dec 6.

Department of Surgery, National Center for Cardiovascular Disease, China & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Electronic address:

Background: Vein graft failure is a crucial challenge in coronary artery bypass graft (CABG) surgery. Previous studies have suggested a patency benefit of the No-Touch vein harvesting technique, but only with small sample sizes.

Materials And Methods: This study is a prospective, multicenter randomized clinical trial with a large sample size, aiming to investigate the efficacy of the No-Touch technique compared with the conventional approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.11.011DOI Listing
December 2018
1 Read

Knowledge of myocardial infarction symptoms and perceptions of self-risk in Tanzania.

Am Heart J 2019 Jan 15;210:69-74. Epub 2019 Jan 15.

Department of Medicine, Duke University Medical Center, 2301 Erwin Rd, Durham, NC.

Background: Little is known about community knowledge of myocardial infarction symptoms and perceptions of self-risk in sub-Saharan Africa.

Methods: A community survey was conducted in northern Tanzania, where the prevalence of cardiovascular risk factors is high. Households were selected randomly in a population-weighted fashion and surveys were administered to self-identified household healthcare decision-makers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.01.003DOI Listing
January 2019
1 Read

Early initiation of extracorporeal life support in refractory out-of-hospital cardiac arrest: Design and rationale of the INCEPTION trial.

Am Heart J 2018 Dec 14;210:58-68. Epub 2018 Dec 14.

Department of Intensive Care, Maastricht University Medical Center, Maastricht, The Netherlands; NUTRIM, School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands; Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands.

Return of spontaneous circulation occurs in less than 10% of patients with cardiac arrest undergoing cardiopulmonary resuscitation (CPR) for more than 15 minutes. Studies suggest that extracorporeal life support during cardiopulmonary resuscitation (ECPR) improves survival rate in these patients. These studies, however, are hampered by their non-randomized, observational design and are mostly single-center. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.12.008DOI Listing
December 2018
1 Read

C-reactive protein and prognosis after percutaneous coronary intervention and bypass graft surgery for left main coronary artery disease: Analysis from the EXCEL trial.

Am Heart J 2019 Jan 11;210:49-57. Epub 2019 Jan 11.

Clinical Trials Center, Cardiovascular Research Foundation, New York, NY; NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, NY. Electronic address:

Background: The prognostic impact of high-sensitivity C-reactive protein (CRP) levels in patients with left main coronary artery disease (LMCAD) treated with percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) is unknown. We sought to determine the effect of elevated baseline CRP levels on the 3-year outcomes after LMCAD revascularization and to examine whether CRP influenced the relative outcomes of PCI versus CABG.

Methods: In the EXCEL trial, patients with LMCAD and Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) scores ≤32 were randomized to PCI versus CABG. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.12.013DOI Listing
January 2019

Heart failure and adverse heart failure outcomes among persons living with HIV in a US tertiary medical center.

Am Heart J 2019 Jan 11;210:39-48. Epub 2019 Jan 11.

Cardiac MR PET CT Program, Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA. Electronic address:

Background: Persons living with HIV (PLHIV) have an increased risk of heart failure (HF). However, little is known about outcomes among PLHIV with HF. The study aim was to compare HF outcomes among PLHIV with HF versus individuals without HIV with HF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.01.002DOI Listing
January 2019
1 Read
4.463 Impact Factor

Rationale and design of the SI! Program for health promotion in elementary students aged 6 to 11 years: A cluster randomized trial.

Am Heart J 2019 Jan 8;210:9-17. Epub 2019 Jan 8.

Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address:

Unhealthy habits in children are increasing at an alarming rate. The school provides a promising setting for effective preventive strategies to improve children's lifestyle behaviors. The SI! Program is a multilevel multicomponent school-based educational intervention aimed at all stages of compulsory education in Spain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.12.011DOI Listing
January 2019

Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.

Am Heart J 2019 Jan 10;210:18-28. Epub 2019 Jan 10.

Department of Epidemiology, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Hirschengraben 84, Zurich, Switzerland. Electronic address:

The current guidelines of statins for primary cardiovascular disease (CVD) prevention were based on results from systematic reviews and meta-analyses that suffer from limitations.

Methods: We searched in PubMed for existing systematic reviews and individual open-label or double-blinded randomized controlled trials that compared a statin with a placebo or another, which were published in English until January 01, 2018. We performed a random-effect pairwise meta-analysis of all statins as a class and network meta-analysis for the specific statins on different benefit and harm outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.12.007DOI Listing
January 2019

Radial versus femoral approach for saphenous vein grafts angiography and interventions.

Am Heart J 2019 Jan 12;210:1-8. Epub 2019 Jan 12.

London Health Sciences Centre, London, Ontario, Canada; Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University, Stoke-on-Trent, United Kingdom; Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada. Electronic address:

Background: Coronary angiography and intervention to saphenous venous grafts (SVGs) remain challenging. This study aimed to investigate the feasibility and safety of the radial approach compared to femoral access in a large cohort of patients undergoing SVG angiography and intervention.

Methods: Data from 1,481 patients from Canada, United States, and Spain who underwent procedures between 2010 and 2016 were collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.11.014DOI Listing
January 2019

Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study.

Am Heart J 2018 Nov 22;209:97-105. Epub 2018 Nov 22.

Department of Cardiology, Bern University Hospital, Bern, Switzerland. Electronic address:

Background: The optimal duration of antiplatelet therapy in high-bleeding risk (HBR) patients with coronary artery disease treated with newer-generation drug-eluting bioresorbable polymer-coated stents remains unclear.

Design: MASTER DAPT (clinicaltrial.govNCT03023020) is an investigator-initiated, open-label, multicenter, randomized controlled trial comparing an abbreviated versus a standard duration of antiplatelet therapy after bioresorbable polymer-coated Ultimaster (TANSEI) sirolimus-eluting stent implantation in approximately 4,300 HBR patients recruited from ≥100 interventional cardiology centers globally. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00028703183030
Publisher Site
http://dx.doi.org/10.1016/j.ahj.2018.10.009DOI Listing
November 2018
4 Reads

Development of a cardiac inherited disease service and clinical registry: A 15-year perspective.

Am Heart J 2018 Dec 19. Epub 2018 Dec 19.

Greenlane Paediatric and Congenital Cardiac Services, Starship Children's Hospital, Auckland, New Zealand. Electronic address:

In 2002, the Cardiac Inherited Diseases Registry New Zealand was established with an associated clinical service, in order to identify pre-symptomatic people with inherited heart conditions, enable tracking of families, and collate data. We describe the establishment of this registry and discuss the key features, including dedicated coordinators, links to a multidisciplinary and collaborative clinical service, a translational research program, a secure web-based database, and governance encompassing ethical and cultural approval. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.11.013DOI Listing
December 2018

Design and rationale of a randomized noninferiority trial to evaluate the SurVeil drug-coated balloon in subjects with stenotic lesions of the femoropopliteal artery - the TRANSCEND study.

Am Heart J 2018 Dec 28;209:88-96. Epub 2018 Dec 28.

The Baim Institute for Clinical Research, Boston, MA; The Brigham and Women's Hospital, Boston, MA.

Background: Drug-coated balloons (DCBs), developed to reduce restenosis after percutaneous intervention in peripheral arterial disease (PAD), have been shown to be safe and efficacious, particularly in treating PAD affecting the femoropopliteal segment. The SurVeil DCB uses an excipient intended to optimize both the uniformity and transfer of paclitaxel to the vessel wall, allowing for efficient drug loading and lower systemic exposure than currently available DCBs, Heretofore, clinical outcomes have not previously been compared to other DCBs.

Study Design And Objectives: This prospective, multicenter, international, randomized, single-blind, trial will compare 1:1 the SurVeil DCB with the IN. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00028703183036
Publisher Site
http://dx.doi.org/10.1016/j.ahj.2018.12.012DOI Listing
December 2018
3 Reads

Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons.

Am Heart J 2018 Dec 20;209:79-87. Epub 2018 Dec 20.

Northwestern University Feinberg School of Medicine, Chicago, IL. Electronic address:

Background: Risks for cardiovascular diseases, including myocardial infarction and stroke, are elevated in people with HIV infection (PWH). However, no trials of statin utilization with clinical cardiovascular disease (CVD) end points have been completed in PWH, and there are sparse real-world data regarding statin use and lipid-lowering effectiveness. We therefore used a unique cohort of PWH and uninfected controls to evaluate (1) differences in statin types used for PWH versus uninfected persons; (2) lipid lowering achieved by statin use for PWH versus uninfected persons; and (3) racial and ethnic disparities in appropriate statin use among PWH and uninfected persons. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.11.012DOI Listing
December 2018
1 Read

Vitamin D with calcium supplementation and risk of atrial fibrillation in postmenopausal women.

Am Heart J 2018 Dec 13;209:68-78. Epub 2018 Dec 13.

Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, CA. Electronic address:

Background: Atrial fibrillation (AF) is the most common arrhythmia in adults. Although vitamin D deficiency is associated with AF risk factors, retrospective studies of association with AF have shown mixed results. We sought to determine the efficacy of calcium and vitamin D (CaD) supplementation for AF prevention in a randomized trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.12.006DOI Listing
December 2018
1 Read

Comparison of the change in heart failure readmission and mortality rates between hospitals subject to hospital readmission reduction program penalties and critical access hospitals.

Am Heart J 2018 Dec 7;209:63-67. Epub 2018 Dec 7.

Stanford University School of Medicine, Stanford, CA; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA.

Background: The Hospital Readmission Reduction Program (HRRP), announced in 2010, penalizes hospitals with high readmissions for multiple conditions including heart failure.

Methods: We compared heart failure readmission and mortality rates in hospitals exposed to HRRP financial penalties with critical access hospitals (CAHs) not subject to the penalty between 2005 and 2016 using 3-year moving averages from Hospital Compare.

Results: After HRRP introduction, CAHs experienced a 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.12.002DOI Listing
December 2018

Generalizability of the FOURIER trial to routine clinical care: Do trial participants represent patients in everyday practice?

Am Heart J 2018 Dec 16;209:54-62. Epub 2018 Dec 16.

Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN. Electronic address:

Background: In the FOURIER trial, evolocumab, a proprotein convertase subtilisin-kexin type 9 inhibitor, reduced cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD). We aimed to examine how closely patients in routine practice resemble the FOURIER trial participants and to assess the observed cardiovascular risks based on trial eligibility and underrepresentativeness.

Methods: Using a large US administrative database with linked laboratory data, we identified adult patients with ASCVD between January 1, 2012, and December 31, 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.09.015DOI Listing
December 2018
2 Reads

A prospective 5-year study of exercise performance following Melody valve implant.

Am Heart J 2018 Dec 29;209:47-53. Epub 2018 Dec 29.

Children's Hospital of Orange County, University of California, Irvine, CA. Electronic address:

Background: The long-term benefits of Melody valve implant for right ventricular outflow tract conduit obstruction or insufficiency on exercise capacity are undefined.

Methods: As part of the Melody valve clinical trial, 136 patients with congenital heart disease underwent serial cardiopulmonary exercise testing prior to, 6 months after, and annually for up to 5 years postimplant.

Results: Mean age at Melody valve implantation was 22. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.12.014DOI Listing
December 2018
1 Read

Clinical and pathologic findings of aortic dissection at autopsy: Review of 336 cases over nearly 6 decades.

Am Heart J 2018 Nov 22. Epub 2018 Nov 22.

Minneapolis Heart Institute Foundation at Abbott-Northwestern Hospital, Minneapolis, MN. Electronic address:

Background: We aimed to characterize the clinical and pathologic findings of aortic dissection (AD) over a nearly 60-year period.

Methods: The Jesse E. Edwards Registry of Cardiovascular Disease database was queried for cardiac specimens from autopsies with AD as a diagnosis and compared 2 cohorts: early (1956-1992) and current (1993-2015). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00028703183032
Publisher Site
http://dx.doi.org/10.1016/j.ahj.2018.11.006DOI Listing
November 2018
7 Reads

Blood kidney injury molecule-1 predicts short and longer term kidney outcomes in patients undergoing diagnostic coronary and/or peripheral angiography-Results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study.

Am Heart J 2018 Dec 7;209:36-46. Epub 2018 Dec 7.

Cardiology Division, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA; Baim Institute for Clinical Research, Boston, MA. Electronic address:

Background: Kidney injury is common in patients with cardiovascular disease.

Objectives: We determined whether blood measurement of kidney injury molecule-1 (KIM-1), would predict kidney outcomes in patients undergoing angiographic procedures for various indications.

Methods: One thousand two hundred eight patients undergoing coronary and/or peripheral angiography were prospectively enrolled; blood was collected for KIM-1 measurement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.12.001DOI Listing
December 2018
2 Reads

Significant mortality, morbidity and resource utilization associated with advanced heart failure in congenital heart disease in children and young adults.

Am Heart J 2018 Dec 5;209:9-19. Epub 2018 Dec 5.

Division of Pediatric Cardiology, The Children's Hospital of Philadelphia, Philadelphia, PA.

Background: Children with congenital heart disease (CHD) are at risk for advanced heart failure (AHF). We sought to define the mortality and resource utilization in CHD-related AHF in children and young adults.

Methods: All hospitalizations in the Pediatric Health Information System database involving patients ≤21 years old with a CHD diagnosis and heart failure requiring at least 7 days of continuous inotropic support between 2004 and 2015 were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.11.010DOI Listing
December 2018
1 Read

New atrial fibrillation diagnosed by 30-day rhythm monitoring.

Am Heart J 2018 Nov 12;209:29-35. Epub 2018 Nov 12.

Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL. Electronic address:

Background: Recent studies of patients with pacemakers and implantable cardioverter/defibrillators have shown that subclinical atrial fibrillation (AF) is common and is associated with thromboembolic risk. We sought to evaluate the frequency, characteristics, and impact of new AF diagnosed by ambulatory 30-day rhythm monitoring.

Methods: The 30-day rhythm monitoring data from January 2010 to August 2015 at our institution were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.11.003DOI Listing
November 2018
2 Reads

Immediate unselected coronary angiography versus delayed triage in survivors of out-of-hospital cardiac arrest without ST-segment elevation: Design and rationale of the TOMAHAWK trial.

Am Heart J 2018 Dec 11;209:20-28. Epub 2018 Dec 11.

Herzzentrum Leipzig-Universitätsklinik für Kardiologie, Leipzig, Germany.

Patients experiencing out-of-hospital cardiac arrest (OHCA) without ST-segment elevation are a heterogenic group with a variety of underlying causes. Up to one-third of patients display a significant coronary lesion compatible with myocardial infarction as OHCA trigger. There are no randomized data on patient selection and timing of invasive coronary angiography after admission. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00028703183034
Publisher Site
http://dx.doi.org/10.1016/j.ahj.2018.12.005DOI Listing
December 2018
9 Reads

How can clinical researchers quantify the value of their proposed comparative research?

Am Heart J 2018 Dec 8. Epub 2018 Dec 8.

Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA.

A research funder faces the challenge of selecting to fund a small set of studies from a larger pool of proposals, even after proposals achieve the benchmarks of scientific rigor and integrity. Clinical researchers can better quantify the value of their proposed study to facilitate this prioritization process. Value of information analysis can help in this quantification and inform the funder about the population and individual patient-level impact of a comparative research proposal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.12.003DOI Listing
December 2018
1 Read

Rationale and design of a randomized clinical trial to assess the safety and efficacy of multipoint pacing therapy: MOre REsponse on Cardiac Resynchronization Therapy with MultiPoint Pacing (MORE-CRT MPP-PHASE II).

Am Heart J 2018 Dec 8;209:1-8. Epub 2018 Dec 8.

Université de Montréal, Montreal, Canada.

Background: Although cardiac resynchronization therapy (CRT) is beneficial in most heart failure patients, up to 40% do not respond to CRT. Data from the MultiPoint Pacing (MPP) IDE trial and MORE-CRT MPP-PHASE I study suggest improved response in subjects in the MPP arm-programmed with wide left ventricular (LV) electrode anatomical separation (≥30 mm) and shortest timing delays of 5 milliseconds (MPP-AS)-compared with quadripolar biventricular (BiV) pacing.

Study Design: The MORE-CRT MPP-PHASE II trial is a prospective, randomized, multicenter study to assess the 6-month impact of MPP programmed to mandated MPP-AS settings in subjects who do not respond to 6 months of BiV pacing (MPP OFF). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00028703183033
Publisher Site
http://dx.doi.org/10.1016/j.ahj.2018.12.004DOI Listing
December 2018
6 Reads

The prognostic value of various biomarkers in adults with pulmonary hypertension; a multi-biomarker approach.

Am Heart J 2018 Nov 24;208:91-99. Epub 2018 Nov 24.

Department of Cardiology, Erasmus Medical Centre, Rotterdam, the Netherlands. Electronic address:

Background: This study aimed to investigate the prognostic value of six different biomarkers in patients with pulmonary hypertension (PH) and to explore whether a multi-biomarker approach can contribute to a better risk stratification.

Methods: In this prospective study, patients with PH were included at the day of the diagnostic right heart catheterization between May 2012 and October 2016. Venous blood sampling included; NT-proBNP, high sensitive troponin-T, high sensitive CRP, galectin-3, red blood cell distribution width and eGFR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.11.001DOI Listing
November 2018
3 Reads

The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction.

Am Heart J 2018 Nov 22;208:81-90. Epub 2018 Nov 22.

Heart and Vascular Center, Semmelweis University, H-1122 Városmajor str 68, Budapest, Hungary.

Background: CSL112 (apolipoprotein A-I [human]) is a plasma-derived apolipoprotein A-I developed for early reduction of cardiovascular risk following an acute myocardial infarction (AMI). The safety of CSL112 among AMI subjects with moderate, stage 3 chronic kidney disease (CKD) is unknown.

Methods: CSL112_2001, a multicenter, placebo-controlled, parallel-group, double-blind, randomized phase 2 trial, enrolled patients with moderate CKD within 7 days following AMI. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00028703183032
Publisher Site
http://dx.doi.org/10.1016/j.ahj.2018.11.008DOI Listing
November 2018
9 Reads
4.463 Impact Factor

The association of pre- and posthospital medication adherence in myocardial infarction patients.

Am Heart J 2018 Nov 15;208:74-80. Epub 2018 Nov 15.

Duke Clinical Research Institute, Durham, NC; Division of Cardiology, Duke University, Durham, NC.

Background: Nonadherence to optimal medical therapy following myocardial infarction (MI) is associated with adverse clinical outcomes such as stent thrombosis, recurrent cardiovascular events, and death. Whether adherence to medications prior to MI predicts post-MI medication adherence is unknown.

Methods: We assessed adherence to P2Y inhibitors and statins before and after admission for MI among 8,147 MI patients who had Medicare insurance with Part D prescription coverage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.11.004DOI Listing
November 2018
6 Reads
4.463 Impact Factor

Modes of death and prognostic outliers in chronic heart failure.

Am Heart J 2018 Nov 24;208:100-109. Epub 2018 Nov 24.

ANMCO Research Centre, Florence, Fondazione per il Tuo cuore - HCF onluse, Florence, Italy. Electronic address:

Background: The impact of incident sudden cardiac death (SCD) on the predictive accuracy of prognostic risk scores for patients with chronic heart failure (HF) has rarely been examined. We assessed the relationship between estimated probability of death and modes of death in this population, as well as the predictors of death and survival in prognostic outliers.

Methods And Results: The MAGGIC 3-year probability of death was estimated in 6,859 participants of the GISSI-HF trial (mean age 67±11 years, 78% men, 91% with ejection fraction <40%, mean follow-up 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.11.009DOI Listing
November 2018
2 Reads
4.463 Impact Factor

Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial.

Am Heart J 2018 Nov 22. Epub 2018 Nov 22.

Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.

Background: Patients with atrial fibrillation (AF) often have multi-morbidity, defined as ≥3 comorbid conditions. Multi-morbidity is associated with polypharmacy, adverse events, and frailty potentially altering response to anticoagulation. We sought to describe the prevalence of multi-morbidity among older patients with AF and determine the association between multi-morbidity, clinical outcomes, and the efficacy and safety of apixaban compared with warfarin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.09.017DOI Listing
November 2018
2 Reads

Aortic dissection-a contemporary revisit of an autopsy series.

Authors:
Toru Suzuki

Am Heart J 2018 Nov 29. Epub 2018 Nov 29.

Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom; NIHR Leicester Biomedical Research Centre, Leicester, United Kingdom; BHF Cardiovascular Centre, Glenfield Hospital, Leicester LE3 9QP, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.11.007DOI Listing
November 2018
1 Read

Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.

Am Heart J 2018 Nov 7;208:65-73. Epub 2018 Nov 7.

Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden; Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.

Background: Clinical Endpoint Classification (CEC) in clinical trials allows FOR standardized, systematic, blinded, and unbiased adjudication of investigator-reported events. We quantified the agreement rates in the STABILITY trial on 15,828 patients with stable coronary heart disease.

Methods: Investigators were instructed to report all potential events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.10.010DOI Listing
November 2018
1 Read

Home monitoring with IT-supported specialist management versus home monitoring alone in patients with heart failure: Design and baseline results of the SUPPORT-HF 2 randomized trial.

Authors:

Am Heart J 2018 Sep 25;208:55-64. Epub 2018 Sep 25.

The George Institute for Global Health, University of Oxford, 1st Floor, Hayes House, 75 George St, Oxford, United Kingdom.

Objectives: SUPPORT-HF 2 tests the hypothesis that home monitoring with information technology-supported specialist management is more effective in optimizing medical therapy than is home monitoring alone for patients with heart failure.

Methods And Results: The study was designed as a 2-armed partially blinded parallel randomized controlled trial. Seven sites in the United Kingdom (UK) recruited a total of 202 adults with heart failure at high risk of adverse outcomes and with potential to benefit from remote management (mean age 73 years, 28% female, median left ventricular ejection fraction 37%). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.09.007DOI Listing
September 2018
3 Reads

Accelerated coronary atherosclerosis not explained by traditional risk factors in 13% of young individuals.

Am Heart J 2018 Nov 13;208:47-54. Epub 2018 Nov 13.

Cardiology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA. Electronic address:

Importance: Most individuals who die of sudden cardiac death (SCD) display very advanced lesions of atherosclerosis in their coronary arteries. Thus, we sought to identify and characterize a putative subpopulation of young individuals exhibiting accelerated coronary artery atherosclerosis.

Objective: Our analysis of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study-which examined 2651 individuals, obtaining quantitative measurements of traditional risk factors for coronary heart disease (CHD)-aimed to identify individuals with advanced coronary artery lesions, and to determine whether risk factors could account for such rapid disease progression, or not. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.11.005DOI Listing
November 2018
1 Read

BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study.

Am Heart J 2018 Oct 25;208:37-46. Epub 2018 Oct 25.

Department of Cardiology, Oslo University Hospital, Ullevaal and Faculty of Medicine, University of Oslo, Oslo, Norway.

Background: Current guidelines on the use of β-blockers in post-acute myocardial infarction (MI) patients without reduced left ventricular ejection fraction (LVEF) are based on studies before the implementation of modern reperfusion and secondary prevention therapies. It remains unknown whether β-blockers will reduce mortality and recurrent MI in contemporary revascularized post-MI patients without reduced LVEF.

Design: BETAMI is a prospective, randomized, open, blinded end point multicenter study in 10,000 MI patients designed to test the superiority of oral β-blocker therapy compared to no β-blocker therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.10.005DOI Listing
October 2018
1 Read

Sex differences in management and outcomes of patients with stable symptoms suggestive of coronary artery disease: Insights from the PROMISE trial.

Am Heart J 2018 Nov 9;208:28-36. Epub 2018 Nov 9.

Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.

Background: Although sex differences exist in the management of acute coronary syndromes, less is known about the management and outcomes of women and men with suspected coronary artery disease being evaluated with noninvasive testing (NIT).

Methods: We investigated sex-based differences in NIT results and subsequent clinical management in 4,720 women and 4,246 men randomized to CT angiography versus stress testing in the PROMISE trial. Logistic regression models assessed relationships between sex and referral for catheterization, revascularization, and aspirin or statin use. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00028703183030
Publisher Site
http://dx.doi.org/10.1016/j.ahj.2018.11.002DOI Listing
November 2018
6 Reads

Attitudes and considerations of patients with ST-elevation myocardial infarction toward participation in randomized clinical trials.

Am Heart J 2018 Nov 7;208:21-27. Epub 2018 Nov 7.

Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.10.011DOI Listing
November 2018
2 Reads

Patterns of use of targeted temperature management for acute myocardial infarction patients following out-of-hospital cardiac arrest: Insights from the National Cardiovascular Data Registry.

Am Heart J 2018 Dec 24;206:131-133. Epub 2018 Sep 24.

Duke Clinical Research Institute, Durham, NC.

Contemporary utilization patterns for targeted temperature management (TTM) among patients with acute myocardial infarction (MI) and out-of-hospital cardiac arrest (OHCA) have not been well characterized in the United States. In this nationwide evaluation of MI patients with OHCA (01/2015-03/2016; 691 hospitals), 34.1% (1792/5260) of OHCA patients received TTM. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00028703183025
Publisher Site
http://dx.doi.org/10.1016/j.ahj.2018.08.013DOI Listing
December 2018
9 Reads

The appropriateness of coronary investigation in myocardial injury and type 2 myocardial infarction (ACT-2): A randomized trial design.

Am Heart J 2018 Oct 25;208:11-20. Epub 2018 Oct 25.

Department of Cardiology, Flinders Medical Centre, Adelaide, Australia; College of Medicine and Public Health, Flinders University of South Australia, Adelaide, Australia. Electronic address:

Background: Elevated troponin level findings among patients presenting with suspected acute coronary syndrome (ACS) or another intercurrent illness undeniably identifies patients at increased risk of mortality. Whilst enhancing our capacity to discriminate risk, the use of high-sensitivity troponin assays frequently identifies patients with myocardial injury (i.e. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00028703183029
Publisher Site
http://dx.doi.org/10.1016/j.ahj.2018.09.016DOI Listing
October 2018
15 Reads

Secular trends in success rate of catheter ablation for atrial fibrillation: The SMASH-AF cohort.

Am Heart J 2018 Oct 29. Epub 2018 Oct 29.

Department of Medicine, Stanford University School of Medicine, Stanford, CA; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA; Center for Digital Health, Stanford University School of Medicine, Stanford, CA. Electronic address:

Background: Approaches, tools, and technologies for atrial fibrillation (AF) ablation have evolved significantly since its inception. We sought to characterize secular trends in AF ablation success rates.

Methods: We performed a systematic review and meta-analysis of AF ablation from January 1, 1990, to August 1, 2016, searching PubMed, Scopus, and Cochrane databases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.10.006DOI Listing
October 2018
3 Reads

Frailty and multi-morbidities should not govern oral anticoagulation therapy prescribing for patients with atrial fibrillation.

Am Heart J 2018 Oct 31. Epub 2018 Oct 31.

Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.10.003DOI Listing
October 2018
2 Reads

Real-world comparison of in-hospital Reveal LINQ insertable cardiac monitor insertion inside and outside of the cardiac catheterization or electrophysiology laboratory.

Am Heart J 2019 Jan 14;207:76-82. Epub 2018 Oct 14.

Electrophysiology Laboratory, The Valley Hospital Health System, One Linwood Avenue, Paramus, NJ. Electronic address:

Background: Traditionally, insertable cardiac monitor (ICM) procedures have been performed in the cardiac catheterization (CATH) or electrophysiology (EP) laboratory. The introduction of the miniaturized Reveal LINQ ICM has led to simplified and less invasive procedures, affording hospitals flexibility in planning where these procedures occur without compromising patient safety or outcomes.

Methods: The present analysis of the ongoing, prospective, observational, multicenter Reveal LINQ Registry sought to provide real-world feasibility and safety data regarding the ICM procedure performed in the CATH/EP lab or operating room and to compare it with insertions performed outside of these traditional hospital settings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.10.002DOI Listing
January 2019
1 Read

Twenty-five year trends (1986-2011) in hospital incidence and case-fatality rates of ventricular tachycardia and ventricular fibrillation complicating acute myocardial infarction.

Am Heart J 2018 Nov 1;208:1-10. Epub 2018 Nov 1.

Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA. Electronic address:

Background: Long-term trends in the incidence rates (IRs) and hospital case-fatality rates (CFRs) of ventricular tachycardia (VT) and ventricular fibrillation (VF) among patients hospitalized with acute myocardial infarction (AMI) have not been recently examined.

Methods: We used data from 11,825 patients hospitalized with AMI at all 11 medical centers in central Massachusetts on a biennial basis between 1986 and 2011. Multivariable adjusted logistic regression modeling was used to examine trends in hospital IRs and CFRs of VT and VF complicating AMI. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00028703183030
Publisher Site
http://dx.doi.org/10.1016/j.ahj.2018.10.007DOI Listing
November 2018
10 Reads

The relationship between pharmacy benefit managers (PBMs) and the cost of therapies in the US pharmaceutical market: A policy primer for clinicians.

Am Heart J 2018 Dec 23;206:113-122. Epub 2018 Aug 23.

Harvard Business School, Boston, MA.

Pharmaceutical benefit managers (PBMs) are playing an increasingly important role in establishing access to pharmaceutical products for patients. PBMs set retail prices for pharmaceutical products, negotiate "rebates" from manufacturers based on total sales volume of products, and achieve several types of postsale price concessions and payments from pharmacies. All of these activities describe a complex flow of funds that has not been transparent to clinicians or to patients. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00028703183024
Publisher Site
http://dx.doi.org/10.1016/j.ahj.2018.08.006DOI Listing
December 2018
12 Reads

Blood pressure differences between home monitoring and daytime ambulatory values and their reproducibility in treated hypertensive stroke and TIA patients.

Am Heart J 2019 Jan 19;207:58-65. Epub 2018 Oct 19.

Ageing and Stroke Medicine Section, Norwich Medical School, Bob Champion Research and Education Building, James Watson Rd, Norwich Research Park, University of East Anglia, Norwich, UK. Electronic address:

Background: Guidelines recommend ambulatory or home blood pressure monitoring to improve hypertension diagnosis and monitoring. Both these methods are ascribed the same threshold values, but whether they produce similar results has not been established in certain patient groups.

Methods: Adults with mild/moderate stroke or transient ischemic attack (N = 80) completed 2 sets of ambulatory and home blood pressure monitoring. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.09.005DOI Listing
January 2019
3 Reads

An international cluster-randomized quality improvement trial to increase the adherence to evidence-based therapies for acute ischemic stroke and transient ischemic attack patients: Rationale and design of the BRIDGE STROKE Trial.

Am Heart J 2019 Jan 30;207:49-57. Epub 2018 Sep 30.

Research Institute HCor-Hospital do Coração, São Paulo, SP, Brazil.

Background: Translating evidence into clinical practice in the management of acute ischemic stroke (AIS) and transient ischemic attack (TIA) is challenging especially in low- and middle-income countries.

Objectives: The aim of this study is to assess the effect of a multifaceted quality improvement intervention on adherence to evidence-based therapies for AIS and TIA patients care.

Design: We designed a pragmatic, 2-arm cluster-randomized trial involving 36 clusters and 1624 patients from Brazil, Argentina, and Peru. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00028703183027
Publisher Site
http://dx.doi.org/10.1016/j.ahj.2018.09.009DOI Listing
January 2019
14 Reads
4.463 Impact Factor

Rationale and design for a cluster randomized quality-improvement trial to increase the uptake of evidence-based therapies for patients at high cardiovascular risk: The BRIDGE-Cardiovascular Prevention trial.

Am Heart J 2019 Jan 17;207:40-48. Epub 2018 Oct 17.

Research Institute HCor - Hospital do Coração, São Paulo, SP, Brazil.

Background: Translating evidence into clinical practice in the management of high cardiovascular risk patients is challenging. Few quality improvement interventions have rigorously evaluated their impact on both patient care and clinical outcomes.

Objectives: The main objectives are to evaluate the impact of a multifaceted educational intervention on adherence to local guidelines for the prescription of statins, antiplatelets and angiotensin converting enzyme inhibitors or angiotensin II receptor blockers for high cardiovascular risk patients, as well as on the incidence of major cardiovascular events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.10.001DOI Listing
January 2019
5 Reads
4.463 Impact Factor